Mutual Fund Details

Nippon India Pharma Fund Direct-Growth

Name: Nippon India Pharma Fund Direct-Growth
Brand: Nippon India Mutual Fund

Equity Pharma

NAV

₹571.3726

as on 26 Dec 2024, 11:16 PM

₹3.0658(0.54%)

Last Change

Scheme Ratings

rated by Value Research

Pharma

Rankings based on | as on Invalid date

Investment Performance

would have given a return of

₹1,10,871

₹1,21,647

₹1,72,596

₹1,77,313

Bank Account

Fixed Deposit

Regular Mutual Fund

This Fund on Paytm Money

This Mutual Fund

₹77,313

Profit (absolute return)

77.31%

in the last

max

+1% Higher Returns

With Direct Plans on Paytm Money

Investment Returns

In the last 3 months

1.43%

In the last 6 months

16.12%

In the last 1 year

34.64%

In the last 3 years

77.31%

In the last 5 years

255.46%

In the last 10 years

359.34%

Absolute Returns

CAGR

Scheme Riskometer

low

low to moderate

moderate

moderately high

high

very high

Investors understand that their principal will be at very high risk

Scheme Information

Nippon India Pharma Fund Direct-Growth

as of 30 Nov 2024, 05:30 AM

₹8,638.23 Cr

Scheme Asset Size

Fund Type

Open-End

Exit Load

Exit load of 1% if redeemed within 1 month.

0.91%

Expense Ratio

Plan

Growth

3.03%

Cash Holding

Benchmark

BSE Healthcare Total Return Index

Scheme Document

View

Benchmark

BSE Healthcare Total Return Index

Exit Load

Exit load of 1% if redeemed within 1 month.

Scheme Document

View

Sectors Holding in this Mutual Fund

as on 30 Nov 2024

Sort By

Value

Sector

Healthcare

96.97%

₹8,376.49 Cr

Cash Holding

3.03%

₹261.74 Cr

Sectors Holding in this Mutual Fund

as on 30 Nov 2024

Sort By

Value

Sector

Healthcare

96.97%

₹8,376.49 Cr

Cash Holding

3.03%

₹261.74 Cr

Companies Holding in this Mutual Fund

as on 30 Nov 2024

Sort By

Value

Company

Sun Pharmaceutical Industries Ltd.

13.47%

₹1,163.57 Cr

Divi's Laboratories Ltd.

8.39%

₹724.75 Cr

Lupin Ltd.

7.67%

₹662.55 Cr

Cipla Ltd.

6.20%

₹535.57 Cr

Dr. Reddy's Laboratories Ltd.

6.05%

₹522.61 Cr

Others

58.22%

₹5,029.18 Cr

View All

Companies Holding in this Mutual Fund

as on 30 Nov 2024

Sort By

Value

Company

Sun Pharmaceutical Industries Ltd.

13.47%

₹1,163.57 Cr

Divi's Laboratories Ltd.

8.39%

₹724.75 Cr

Lupin Ltd.

7.67%

₹662.55 Cr

Cipla Ltd.

6.20%

₹535.57 Cr

Dr. Reddy's Laboratories Ltd.

6.05%

₹522.61 Cr

Others

58.22%

₹5,029.18 Cr

View All

Funds in this Category

This fund's returns:

21.02%

Return Duration

3 Years

ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth

SBI Healthcare Opportunities Fund Direct Plan-Growth

Tata India Pharma & HealthCare Fund Direct-Growth

About Nippon India Pharma Fund Direct-Growth

Nippon India Pharma Fund Direct-Growth is a Equity mutual fund scheme from Nippon India Mutual Fund. This scheme was launched on Invalid date. It has an AUM of ₹8,638.23 Crores and the latest NAV decalared is ₹571.373 as on 27 Dec 2024 at 4:27 am.

Nippon India Pharma Fund Direct-Growth scheme return performance in last 1 year is 34.64%, in last 3 years is 77.31% and 713.44% since scheme launch. The min. SIP amount to invest in this scheme is ₹100.